BioCentury on BioBusiness,
Monday, August 14, 2000
Market value tracking: Sepracor Inc. (SEPR)
Down, but hardly out
Sepracor's 21 percent slide to $98.125 last week may have
left recent investors below water, but those who bought the stock in the second
half of 1999 are still sitting on profits.
SEPR's tumble last week was triggered by a court decision that
could open up the door to generic competition for partner Eli Lilly's Prozac
as early as next February, before the pharma company can complete development
of SEPR's pure R-enantiomeric form of the anti-depressant drug (see
Technology Briefing, A7).
SEPR spent most of the second half of 1999 between the mid-$30s and the mid-$50s (split adjusted). Friday's close puts the stock in the middle of its 52-week range of $32.75 to $140. SEPR hit the 52-week high in early July, and had more than recouped its losses from the March biotech sell-off. The shares, which had traded in the low $120s, dipped to the low $70s through mid-April before making the run to $140.
The chart shows the weekly change in the indexed market value of SEPR (dotted line with triangles) compared to The Carson 2000 Tier I Index of 20 large cap companies (>$1B, solid line with squares). The initial index value is100 as of Dec. 31, 1998. SEPR's market cap is about $7.2 billion.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]